Review article: Pharmacological approaches to the optimal control of nocturnal intragastric acidity

Alimentary Pharmacology and Therapeutics Symposium Series

Volumn 3, Issue 1, 2007, Pages 39-45

  Howden, C W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; ESOMEPRAZOLE; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PEPSIN A; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

ADD ON THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DELAYED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; ENTERIC COATED TABLET; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; NOCTURNAL INTRAGASTRIC ACIDITY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH DISEASE; STOMACH PH;

EID: 34247885789     PISSN: 17466334     EISSN: 17466342     Source Type: Journal    
DOI: 10.1111/j.1746-6342.2006.00072.x     Document Type: Conference Paper

References (24)

1. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998 93 : 763 7.
2. Tutuian R, Katz P, Castell D. A PPI is a PPI is a PPI: lessons from prolonged intragastric pH monitoring [Abstract]. Gastroenterology 2000 118 : A17.
3. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998 12 : 1235 40.
4. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 100 : 190 200.
5. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005 21 : 1467 74.
6. Katz P, Ballard D, Koch F, et al. Nocturnal gastric acidity after bedtime dosing of proton pump inhibitors in patients with nighttime GERD symptoms [Abstract]. Gastroenterology 2006 130 : A175.
7. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992 51 (Suppl. 1 59 67.
8. Horn JR, Howden CW. Review article: Similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005 22 (Suppl. 3 20 4.
9. Howden CW, Meredith PA, Forrest JA, Reid JL. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 1984 26 : 641 3.
10. Howden CW, Forrest JA, Meredith PA, Reid JL. Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man. Br J Clin Pharmacol 1985 20 : 137 9.
11. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991 20 : 38 49.
12. Maton PN. Omeprazole. N Engl J Med 1991 324 : 965 75.
13. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998 56 : 307 35.
14. McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol 2005 3 : 553 63.
15. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998 115 : 1335 9.
16. Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999 13 : 675 8.
17. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002 122 : 625 32.
18. Vakil N, Guda N, Partington S. The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. Aliment Pharmacol Ther 2006 23 : 649 53.
19. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005 100 : 1237 42.
20. Hepburn B, Goldlust B. Comparative effects of an omeprazole antacid complex-immediate release (OACIR) and omeprazole delayed-release (OME-DR) on omeprazole pharmacokinetics and gastric pH in healthy subjects [Abstract]. Gastroenterology 2003 124 : A228.
21. Howden CW. Review article: Immediate-release proton-pump inhibitor therapy - potential advantages. Aliment Pharmacol Ther 2005 22 (Suppl. 3 25 30.
22. Feurle GE. The action of antacids on serum gastrin concentrations in man. Klin Wochenschr 1977 55 : 1039 42.
23. Hila A, Castell DO. Nighttime reflux is primarily an early event. J Clin Gastroenterol 2005 39 : 579 83.
24. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006 23 : 1473 7.